drug
esketamine hydrochloride
Marketedupdated 5mo agoby Johnson & Johnson Innovative Medicine
Approvedannual revenue · 2024–2024peak $1.0B
community read0 votes
🐶 often sniffed alongside
top 5indications
investigational
Major Depression
all catalysts(1)
Trials studying esketamine hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 20, 2027
171 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Feb 18, 2040method-of-use (U-3813)US 11883526
- Sep 10, 2035method-of-use (U-3036)US 10869844
- Sep 10, 2035method-of-use (U-3257)US 11173134
- Sep 10, 2035method-of-use (U-3035)US 11311500
- Mar 14, 2034method-of-use (U-3446)US 11446260
- Mar 5, 2033method-of-use (U-4112)US 8785500
- Mar 20, 2027method-of-use (U-4112)US 9592207171d
FDA exclusivities (1)
- Jan 17, 2028I-959Indication (3y)1.3y
News(10)
- How J&J paved the way for Compass’ coming psychedelic drug launchIn an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…biopharma_dive · 8d ago
- Deep dive: Psychedelics back on FDA’s doorstepBioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.biospace · 13d ago
- Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near marketSafety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…biospace · 14d ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 15d ago
- Psychedelics on the cusp of market breakthrough as clinical, policy support growWhile there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.biospace · 1mo ago
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 2mo ago
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…biospace · 2mo ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 2mo ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 2mo ago
- Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeoverWith the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that